Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) Sees Significant Growth in Short Interest

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) was the target of a large increase in short interest in the month of January. As of January 15th, there was short interest totaling 192,015 shares, an increase of 81.0% from the December 31st total of 106,098 shares. Based on an average trading volume of 194,094 shares, the short-interest ratio is presently 1.0 days. Approximately 1.4% of the company’s shares are short sold. Approximately 1.4% of the company’s shares are short sold. Based on an average trading volume of 194,094 shares, the short-interest ratio is presently 1.0 days.

Institutional Investors Weigh In On Kairos Pharma

A number of institutional investors have recently added to or reduced their stakes in KAPA. FNY Investment Advisers LLC acquired a new position in Kairos Pharma in the 3rd quarter valued at approximately $27,000. XTX Topco Ltd bought a new stake in shares of Kairos Pharma during the second quarter valued at approximately $44,000. Finally, Two Sigma Investments LP acquired a new position in shares of Kairos Pharma in the third quarter valued at $54,000.

Analyst Upgrades and Downgrades

Separately, D. Boral Capital reaffirmed a “buy” rating and issued a $9.00 target price on shares of Kairos Pharma in a research report on Wednesday, November 19th. Three research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $8.33.

Kairos Pharma Stock Down 0.1%

NYSEAMERICAN KAPA traded down $0.00 during trading on Friday, hitting $0.66. The company’s stock had a trading volume of 126,041 shares, compared to its average volume of 181,725. Kairos Pharma has a 52 week low of $0.40 and a 52 week high of $2.11. The firm has a market cap of $13.83 million, a P/E ratio of -2.14 and a beta of 2.28. The firm has a 50 day moving average price of $0.79 and a 200 day moving average price of $1.02.

Kairos Pharma (NYSEAMERICAN:KAPA) last announced its quarterly earnings data on Friday, November 14th. The company reported ($0.07) earnings per share (EPS) for the quarter.

Kairos Pharma Company Profile

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical?stage biopharmaceutical company focused on developing small?molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full?length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.